Maccura Cost Of Revenue from 2010 to 2024

300463 Stock   13.84  0.72  4.95%   
Maccura Biotechnology's Cost Of Revenue is increasing over the years with slightly volatile fluctuation. Cost Of Revenue is expected to dwindle to about 1.1 B. From 2010 to 2024 Maccura Biotechnology Cost Of Revenue quarterly data regression line had arithmetic mean of  925,096,301 and r-squared of  0.75. View All Fundamentals
 
Cost Of Revenue  
First Reported
2014-03-31
Previous Quarter
262.5 M
Current Value
287.4 M
Quarterly Volatility
135.3 M
 
Yuan Drop
 
Covid
Check Maccura Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Maccura Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 28.5 M, Selling General Administrative of 478.8 M or Total Revenue of 2.5 B, as well as many indicators such as . Maccura financial statements analysis is a perfect complement when working with Maccura Biotechnology Valuation or Volatility modules.
  
This module can also supplement various Maccura Biotechnology Technical models . Check out the analysis of Maccura Biotechnology Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Maccura Stock

Maccura Biotechnology financial ratios help investors to determine whether Maccura Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Maccura with respect to the benefits of owning Maccura Biotechnology security.